HaCaT as well as human primary keratinocytes constitutively expressed mRNA of the human secreted phospholipase A 2 subtype groups X, V, IIA, and IID. A similar expression pattern was also found in human skin biopsies. Protein analysis showed that under serum-free conditions only group X secreted phospholipase A 2 is secreted into cell culture supernatants of HaCaT as well as human primary keratinocytes, whereas the other secreted phospholipases A 2 were not detectable at protein level. HaCaT keratinocytes constitutively released secreted phospholipase A 2 activity into the cell culture supernatant, being re¯ected by a constant release of fatty acids. The phorbol ester 12-O-tetradecanoylphorbol-13-acetate, which is a potent inducer of in¯ammation in skin, drastically reduced the mRNA level of group X secreted phospholipase A 2 and other secreted phospholipase A 2 subtypes as well as secreted phospholipase A 2 activity in cell culture supernatants. This suggests that inhibition of secreted phospholipase A 2 expression and activity as well as of fatty acid release by 12-O-tetradecanoylphorbol-13-acetate treatment might be a critical step impairing the integrity of the epidermis during phorbol-ester-induced pathologic processes in skin. The results show that group X secreted phospholipase A 2 represents the major secreted phospholipase A 2 subtype in human keratinocytes and thus may indicate a physiologic role for this enzyme in epidermis in vivo. Key words: epidermal homeostasis/in¯ammation/phospholipase A2 inhibitors/ skin. J Invest Dermatol 116: 31±39, 2001 
HaCaT as well as human primary keratinocytes constitutively expressed mRNA of the human secreted phospholipase A 2 subtype groups X, V, IIA, and IID. A similar expression pattern was also found in human skin biopsies. Protein analysis showed that under serum-free conditions only group X secreted phospholipase A 2 is secreted into cell culture supernatants of HaCaT as well as human primary keratinocytes, whereas the other secreted phospholipases A 2 were not detectable at protein level. HaCaT keratinocytes constitutively released secreted phospholipase A 2 activity into the cell culture supernatant, being re¯ected by a constant release of fatty acids. The phorbol ester 12-O-tetradecanoylphorbol-13-acetate, which is a potent inducer of in¯ammation in skin, drastically reduced the mRNA level of group X secreted phospholipase A 2 and other secreted phospholipase A 2 subtypes as well as secreted phospholipase A 2 activity in cell culture supernatants. This suggests that inhibition of secreted phospholipase A 2 expression and activity as well as of fatty acid release by 12-O-tetradecanoylphorbol-13-acetate treatment might be a critical step impairing the integrity of the epidermis during phorbol-ester-induced pathologic processes in skin. The results show that group X secreted phospholipase A 2 represents the major secreted phospholipase A 2 subtype in human keratinocytes and thus may indicate a physiologic role for this enzyme in epidermis in vivo. Key words: epidermal homeostasis/in¯ammation/phospholipase A2 inhibitors/ skin. J Invest Dermatol 116: 31±39, 2001 S ecreted phospholipases A 2 (sPLA 2 s) comprise a subfamily of phospholipases A 2 that are structurally related but display only modest sequence homology (Cupillard et al, 1997; Valentin et al, 1999) . Many studies show that the induction and activity of mammalian sPLA 2 subtypes are involved in proin¯ammatory processes in several tissues and organs inducing or enhancing arachidonic acid release and prostaglandin formation (Pfeilschifter et al, 1993; Hurt-Camejo et al, 1997; Jamal et al, 1998; Pruzanski et al, 1998; Han et al, 1999; Murakami et al, 1999; Schiering et al, 1999; Shoda et al, 1999) . Recently, the existence of several sPLA 2 subtypes within the same cell and the location to different subcellular sites was described (Bingham et al, 1999) . In several cell systems treatment with proin¯ammatory cytokines resulted in the induction of group IIA sPLA 2 at the transcriptional level. Group IIA sPLA 2 protein is present in secretory vesicles (Vervoordeldonk et al, 1994; Bingham et al, 1999 ) from which it is released into the extracellular lumen. sPLA 2 s are thought to be involved in in¯ammatory processes, e.g., in the kidney (Pfeilschifter, 1994) , the joints (Jamal et al, 1998) , or the skin (Andersen et al, 1994) . Detailed studies concerning the regulation of group IIA sPLA 2 have been performed, e.g., in rat glomerular mesangial cells, which release this enzyme in large amounts after stimulation with in¯ammatory cytokines such as interleukin-1b (IL-1b) or cAMP-elevating agents (for review see Pfeilschifter, 1994 Pfeilschifter, , 1995 Pfeilschifter et al, 1997) .
In contrast, group V sPLA 2 was identi®ed in heart, mast cells, and macrophages and seems to be a major enzyme involved in arachidonic acid release and prostaglandin formation (Chen and Dennis, 1998; Sawada et al, 1999; Shinohara et al, 1999) . The group IIA and the group V sPLA 2 s are thought to be functionally redundant (Murakami et al, 1998) . It has been reported that these enzymes show differences in their substrate speci®city concerning the phospholipid head groups, however, suggesting that group V sPLA 2 works better on biologic membranes than group IIA sPLA 2 (Han et al, 1999; Janssen et al, 1999) . Moreover, Bingham et al (1999) unraveled the subcellular location of these sPLA 2 subtypes in bone-marrow-derived mast cells, showing that group V is located in perinuclear membranes similarly to enzymes involved in eicosanoid biosynthesis, whereas group IIA sPLA 2 is present in secretory granules for exocytosis. This study implies that these enzymes exert different functions and thus they are not redundant.
The group IIC sPLA 2 was found in testis of rat and mouse and seems to be a nonfunctional pseudogene in humans (Tisch®eld, and fertilization in rodent testis (Chen et al, 1997) . Several novel subtypes identi®ed are the group IID, IIE, IIF, and X sPLA 2 s, which are found in different murine tissues (Valentin et al, 1999) . A group IID and recently also a group IIE were identi®ed in human tissues (Ishizaki et al, 1999; Suzuki et al, 2000) , but a human ortholog has not been found so far for group IIF sPLA 2 . The functions of most of these novel sPLA 2 subtypes remain to be elucidated.
A human group X sPLA 2 was found to be expressed in tissues related with in¯ammatory responses (Cupillard et al, 1997) as well as in alveolar epithelial cells of human lung (Hanasaki et al, 1999) . This sPLA 2 subtype has speci®c structural features and its chromosomal location is distinct from those of other sPLA 2 s (Cupillard et al, 1997) . Group X sPLA 2 was found to release arachidonic acid more ef®ciently than other human sPLA 2 groups when added exogenously to mammalian cells, implicating a potential role in eicosanoid biosynthesis (Hanasaki et al, 1999; Bezzine et al, 2000) .
In the skin, however, a function of sPLA 2 distinct from in¯ammation was described. The catalytic action of sPLA 2 was found to be crucial for epidermal homeostasis, which is important for keeping the membrane permeability barrier intact against excess water loss ( Mao-Qiang et al, 1995 . This permeability barrier is located within the extracellular, lipid-enriched domain of the stratum corneum (Lampe et al, 1983) . In this domain sPLA 2 and many other lipid-hydrolyzing enzymes such as sphingomyelinase, triacylglycerol hydrolase, as well as certain proteases were identi®ed in lamellar granules (also called lamellar bodies; Tinois et al, 1989) . These are secretory organelles responsible for delivering lipids into the intercellular space building up the permeability barrier. The function of sPLA 2 is to hydrolyze free fatty acids from polar lipids to form more nonpolar lipids, which predominate in the stratum corneum. This action of sPLA 2 might be an important process for the maintenance of epidermal integrity but also during wound healing and skin repair. Only little information is yet available, however, as to which sPLA 2 subtypes exist in the human skin and how individual subtypes contribute to the structural and functional integrity of skin. Recent studies describe the localization of the pancreatic group IB sPLA 2 between the stratum corneum and stratum granulosum of human skin, but group IIA sPLA 2 was not found (Maury et al, 2000; Mazereeuw-Hautier et al, 2000) . Other sPLA 2 subtypes were not considered in this study, however.
Using the human keratinocyte cell line HaCaT, human primary keratinocytes, and human skin biopsies we identi®ed mRNAs of the sPLA 2 subtypes IIA, IID, V, and X with group X sPLA 2 being the predominant species. On the protein level we detected only group X sPLA 2 in cell lysates and cell culture supernatants of HaCaT cells and human primary keratinocytes cultured under serum-free conditions, indicating that this is the major enzyme secreted by these cells under these conditions. Moreover, we show that the potent in¯ammatory phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibited the mRNA expression of group X sPLA 2 and also of the other sPLA 2 subtypes.
MATERIALS AND METHODS
Cell culture HaCaT cells (Boukamp et al, 1988) were cultured routinely in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), penicillin (100 units per ml), and streptomycin (100 mg per ml). For experiments, cells were transferred to plastic Petri dishes (Falcon, 3.5 cm with 1 ml medium or 10 cm diameter with 5 ml medium) and cultured for 72 h in DMEM containing 2.5% FBS to subcon¯uency. Twenty-four hours prior to the experiment the serum concentration was further reduced to 0.25% FBS. During the time course of the experiments cells were kept in DMEM without serum. For analysis of fatty acid release HaCaT cells were kept in DMEM plus 0.1% fatty-acidfree bovine serum albumin (BSA).
Human primary keratinocytes were cultured in serum-free keratinocyte medium KBM2 (Clonetics) using standard protocols as described earlier (Stein et al, 1997) .
Analysis of sPLA 2 mRNA expression by reverse transcriptase polymerase chain reaction (RT-PCR) HaCaT as well as human primary keratinocyte cell cultures were washed twice with phosphatebuffered saline (PBS) and harvested using a rubber policeman. Total cellular RNA was extracted from the cell pellets using the guanidinium isothiocyanate-phenol-chloroform method (Sambrook et al, 1989) .
Human skin samples, which were frozen in liquid nitrogen immediately after surgery, were homogenized in guanidinium isothiocyanate with an ultra-turrax-homogenizer and RNA was extracted as described above. For excluding contamination with DNA, treatment of RNA preparations with RNase-free DNase I (Roche Diagnostics, Mannheim, Germany) was performed before RT-PCR.
Expression of mRNA for the different sPLA 2 subtypes was investigated by RT-PCR using a total of 5 mg of RNA. First strand cDNA was transcribed with superscript II RNase H-RT obtained from Gibco BRL and OligodT 15-Primer (Promega). From the reverse transcriptase product (cDNA) aliquots of 500 ng were taken for PCR with the primers to be tested. From poly-A + mRNA of lung 0.1 mg were used for the reverse transcription and an aliquot corresponding to 20 ng of cDNA was taken for PCR. PCR was performed on a Perkin Elmer Thermal Cycler with speci®c primers for each subtype and REDTaq DNA polymerase (Sigma, Munich, Germany): group IB, sense, 5¢-aactccttgtgctagctgtgct-3¢; antisense, 5¢-cttcttggtgtccaggttct, ampli®ed product 428 bp; group IIA, sense, 5¢-gactgttgctacaaacgtctggag-3¢; antisense, 5¢-aggagagcagtagaaggctggaaa-3¢, ampli®ed product 437 bp; group IID, sense, 5¢-ggtcaagcaagtgactggaaaatg-3¢; antisense, 5¢-agaaacgcagtcgcttctggtaggt-3¢, ampli®ed product 311 bp; group V, sense, 5¢-acattcgcacacagtcctac-3¢; antisense, 5¢-tgagttggaggagagctctt-3¢, ampli®ed product 452 bp; group X, sense, 5¢-ccaggatattacgtgtgcac-3¢; antisense, 5¢-gtttgggctaagcagttagc-3¢, ampli®ed product 327 bp; glyceraldehyde-3-phosphate dehydrogenase (GAPDH), sense, 5¢-accacagtccatgccatcac-3¢; antisense, 5¢-tccaccaccctgttgctgta-3¢, ampli®ed product 452 bp.
Semi-quantitative RT-PCR For semiquantitative RT-PCR the number of ampli®cation steps was tested ®rst for linearity with different dilutions of reverse transcriptase product. Then GAPDH was performed for an equivalent quantity of the reverse transcriptase reaction. The different cDNA probes were ampli®ed in a prepared mastermix containing dNTPs, speci®c primers, and Red Taq-polymerase (Sigma) in the corresponding PCR buffer.
For the PCR reactions the cycling parameters were optimized as follows: group IIA, 94°C for 1 min (one cycle) followed immediately by 94°C for 1 min, 60°C for 1 min 30 s, and 72°C for 3 min (32 cycles); group IID, 94°C for 1 min followed immediately by 94°C for 30 s, 60°C for 30 s, and 72°C for 30 s (36 cycles); group V, 94°C for 1 min (one cycle) followed immediately by 94°C for 30 s, 54°C for 45 s, and 72°C for 2 min (33 cycles); group X, 94°C for 1 min (one cycle) followed immediately by 94°C for 30 s, 50°C for 30 s, and 72°C for 30 s (34 cycles); GAPDH, 94°C for 1 min (one cycle) followed immediately by 94°C for 1 min, 60°C for 1 min, and 72°C for 2 min (23 cycles).
Final extension phase for the PCRs of all subtypes was 10 min at 72°C. PCR products were separated on 2% agarose gels containing 0.5 mg per ml ethidium bromide and were visualized with an ultraviolet-gel camera (Biorad, Munich, Germany).
Northern blot analysis Samples of 30 mg of RNA were separated on 1.4% agarose/formaldehyde gels and transferred to a Gene Screen membrane. After ultraviolet crosslinking and prehybridization in Ultrahyb buffer (Ambion, Austin, TX) for 1 h the ®lters were hybridized in Ultrahyb buffer for 16 h at 68°C to [a-32 P]dCTP-labeled cDNA inserts from groups IIA, V, and X sPLA 2 . DNA probes were radioactively labeled with [a-32 P]dCTP by random priming. Finally, the ®lters were washed twice with 2 Q sodium citrate/chloride buffer (SSC)/0.1% sodium dodecyl sulfate (SDS) for 2 Q 10 min and several times at 68°C with 0.1 Q SSC/ 0.1% SDS. The signal was detected and quanti®ed with a phosphorimager BAS 1500 from Fuji (Raytest, Straubenhardt, Germany). To correct for variations in RNA loading the respective cDNA probes were stripped and the blots were hybridized for 16 h with Ultrahyb buffer at 42°C to the [a-32 P]dCTP-labeled cDNA insert for GAPDH. The numbers at the top of the northern blot represent the corrected density expressed as the percentage of group X sPLA 2 mRNA found in cells at time point zero.
sPLA 2 activity assay sPLA 2 activity in the supernatant of HaCaT cells was determined with [1-14 C]-oleate-labeled membranes from Escherichia coli as a substrate as described previously (Scholz et al, 1999) . Assay mixtures (750 ml) contained 100 mM Tris/HCl (pH 7.0), 1 mM CaCl 2 , [1-14 C]-oleate-labeled E. coli membranes (approximately 5000 cpm), and the enzyme-containing supernatants of the cell cultures. During incubation less than 5% of substrate was hydrolyzed. The reaction mixture was incubated for 1 h at 37°C in a thermomixer. The reaction was stopped by the addition of 50 ml 1 mM ethyleneglycol-bis(b-aminoethyl ether)-N,N,N¢,N¢-tetraacetic acid (EGTA)/1 N HCl and 800 ml ethyl acetate. After extraction of the lipids the organic phase was dried in a vacuum concentrator. Then the lipids were dissolved in 50 ml ethyl acetate and separated by thin layer chromatography on silica gel G 60 plates using the organic phase of ethyl acetate:isooctane:acetic acid:water (110:50:20:100 by volume) as a solvent system. Detection and quanti®cation of the released fatty acid were performed with a linear analyzer (Berthold, Wildbad, Germany). In parallel experiments extraction ef®ciency was determined to be greater than 95%.
Measurement of fatty acid release For measuring fatty acid release HaCaT cells were cultured in 3.5 cm dishes to subcon¯uency (about 10 6 cells per dish) in 2 ml cell culture medium. After medium change cells were prelabeled for 24 h with [1-14 C]-linoleic acid or [1-14 C]-oleic acid (0.3 mCi per ml) in 1 ml DMEM plus 1 mg per ml fatty-acid-free BSA. After washing the cell cultures twice with PBS/BSA (1 mg per ml) and adding 1 ml of fresh medium the supernatants were collected at different time points as indicated. Supernatants were measured in a b-counter to detect the amounts of released [1-14 C]-labeled fatty acids. The incorporation rate of the different fatty acids into keratinocytes was evaluated by extracting the cells with chloroform:methanol:1 N HCl (4:2:2 by volume) and measuring the radioactivity of the organic phase in a b-counter. For all three fatty acids the incorporation rate after 24 h was about 90%. The amounts of labeled fatty acids in the supernatants represent about 0.2% of total labeled lipids. The amount of lipid peroxidation products derived nonenzymatically or enzymatically from linoleic acid under the conditions of prelabeling did not exceed 5% (unpublished observation).
Western blot analysis sPLA 2 protein secretion by HaCaT cells was assayed by precipitating 5 ml of the culture supernatants with 2 ml of 20% trichloroacetic acid. SDS polyacrylamide gel electrophoresis (PAGE) using a 15% polyacrylamide gel was performed under nonreducing conditions according to Laemmli (1970) . Cell lysates were obtained after removal of the medium by incubating the cell layer on ice for 10 min in 500 ml per 10 cm dish of 50 mM Tris/HCl pH 7.5, 150 mM NaCl, 1 mM phenylmethylsulfonyl¯uoride, 10 mg per ml leupeptin, 0.5% Triton X-100. One milligram of cellular protein was diluted in 150 ml Laemmli sample buffer and was separated on a 14 cm Q 14 cm polyacrylamide gel with 8 mm slots. As controls 500 ng of human recombinant groups IIA and X sPLA 2 protein were also loaded on the gel. For western blotting proteins were transferred to PVDF membranes for 30 min at 0.8 mA per cm 2 . Nonspeci®c binding was blocked with 2% (wt/vol) BSA in PBS-Tween 20 for 1 h at room temperature followed by incubation with a 1:100 dilution of a primary antibody against the human group X sPLA 2 . The antiserum was generated in rabbits against the peptide PKTERYSWQC (amino acid sequence 101±111; Cupillard et al, 1997) , conjugated to keyhole limpet hemocyanin. Then the blot was incubated with horseradish-peroxidaseconjugated goat antirabbit IgG. After washing, peroxidase activity was detected by developing the blots by the enhanced chemiluminescence method (Amersham, Freiburg, Germany). The minimum amount of group X sPLA 2 protein recognized by the serum at 1:100 dilution is 300±400 ng. Calculation of the amounts of group X sPLA 2 protein on the western blots was performed by densitometric analysis using human recombinant group X protein as standard in a range of 500 ng to 1 mg.
Cross-reactivity of this antiserum with other human and murine sPLA 2 subtypes was tested by loading 500 ng of the respective recombinant, refolded proteins (human groups IB, IIA, IID, V, X) on a gel and performing PAGE and western blot analysis with a 1:100 dilution of the human group X antiserum under nonreducing conditions. The source of all these enzymes will be given elsewhere. The structures of the proteins were con®rmed by electrospray mass spectrometry to show that all disul®des were intact.
Enzyme-linked immunosorbent assay (ELISA) for analysis of sPLA 2 protein In order to detect group IIA sPLA 2 in the cell culture supernatants of HaCaT cells an ELISA from Boehringer Mannheim (Mannheim, Germany) designed against the human group IIA sPLA 2 was performed according to the manufacturer's instructions. This ELISA detects puri®ed human group IIA sPLA 2 in a range of 1-500 ng per ml. To analyze a cross-reaction of the sPLA 2 antibody used in this ELISA with other sPLA 2 subtypes, up to 500 ng of puri®ed human recombinant protein of the group V sPLA 2 , kindly provided by Dr. Wonhwa Cho (Department of Chemistry, University of Illinois, Chicago, IL), and also 500 ng of the group X were used as positive controls. We found that the antibody against the human group IIA used as standard in this ELISA cross-reacted with human group V sPLA 2 . In the standard curve both enzymes were detected with an equal sensitivity, whereas group X sPLA 2 was not detected (data not shown).
Statistical analysis Data are presented as mean T SEM resulting from three independent experiments performed in triplicate (n = 3), or mean T SD when showing one representative experiment out of three performed in triplicate.
Statistical analysis was performed by Student's t test to determine signi®cant differences among two groups. *, #, +p < 0.05. For comparing all LY-311727 concentrations with the control group statistical analysis was performed by repeated measures ANOVA followed by Dunnett's test. A probability less than 0.05 was de®ned as signi®cant. Immobilon-PVDF membranes were from Millipore (Eschborn, Germany) and Nylon membranes (Gene Screen) were purchased from NEN Life Science (Ko Èln, Germany). All cell culture media and nutrients were from Gibco BRL (Eggenstein, Germany), and all other chemicals used were from Merck (Darmstadt, Germany), Sigma (Munich, Germany), or Fluka (Deisenhofen, Germany).
Materials

RESULTS
mRNA expression of sPLA 2 subtypes in HaCaT keratinocytes, in human keratinocytes, and in human skin mRNA was extracted from subcon¯uent HaCaT cell cultures grown under serum-free conditions, and RT-PCRs were performed under the conditions described in Methods with a set of primers speci®c for the human groups IB, IIA, IID, V, and X sPLA 2 s. The identity of the PCR products was con®rmed by sequence analysis.
The qualitative analysis shown in Fig 1(a) indicates that under serum-free conditions HaCaT cells constitutively express groups IIA, IID, V, and X sPLA 2 mRNA. Southern blot analysis indicated that group X sPLA 2 is the predominant sPLA 2 subtype expressed in HaCaT cells (data not shown). According to this analysis, sPLA 2 subtypes can be ranked in the following order: group X > group V > group IIA > group IID. As the group IID sPLA 2 mRNA is present only at very low levels (indicated by the arrows in the lanes of group IID sPLA 2 ) we did not further study the expression of this subtype.
In order to compare the mRNA expression pattern of sPLA 2 subtypes in HaCaT cells with that in human primary keratinocytes and in human skin, total RNA from cell cultures of human primary keratinocytes and from human biopsies was extracted and RT-PCR was performed with primer sets speci®c for the sPLA 2 groups IB, IIA, IID, V, and X. The data in Fig 1(a) show the same expression pattern as for HaCaT cells: groups IIA, IID, V, and X sPLA 2 mRNA are constitutively expressed both in human primary keratinocytes and in the human skin biopsies.
With the primers and under the experimental conditions used group IB sPLA 2 mRNA was not detected in HaCaT cells and in human primary keratinocytes and human skin in vivo (Fig 1b) . As positive control for group IB sPLA 2 RT-PCR with the primers was performed with poly A + RNA from human lung, which is known to express this sPLA 2 subtype (Matsuda et al, 1987) .
Detection of sPLA 2 protein in HaCaT cells and in human primary keratinocytes by western blot analysis To study the subtypes of sPLA 2 secreted from HaCaT cells and human primary keratinocytes, we performed western blot analysis of protein precipitated from cell culture supernatants and cell lysates from cells cultured under serum-free conditions.
Using an antiserum raised against a group X sPLA 2 -speci®c peptide, strong immunoreactivity towards puri®ed recombinant human group X sPLA 2 , but no cross-reactivity with puri®ed recombinant human groups IB, IIA, IID, or V sPLA 2 proteins, was observed (Fig 2a) .
With this antiserum group X sPLA 2 protein was detectable in the cell culture supernatants of HaCaT cells as well as human primary keratinocytes (Fig 2b) . The concentration of group X protein released into the supernatant was determined by densitometric analysis to 200 ng per ml.
In order to analyze whether there is also group IIA or group V sPLA 2 present in cell culture supernatants of HaCaT cells and human primary keratinocytes, we used an ELISA from Boehringer Mannheim, which detects both sPLA 2 subtypes in a range between 1 and 500 ng per ml (see Methods). As positive controls for standard curves we used up to 500 ng of both human recombinant group IIA and group V sPLA 2 . With this method we did not detect a positive signal in the cell culture supernatants of HaCaT cells or human primary keratinocytes, indicating that group IIA and group V sPLA 2 are not secreted by these cells (data not shown).
Group X sPLA 2 was also detectable in cell lysates of HaCaT cells as well as human primary keratinocytes (Fig 2c) . From these results we conclude that the group X sPLA 2 is the major enzyme secreted by keratinocytes under serum-free conditions.
Detection of sPLA 2 activity in the supernatants of HaCaT cell cultures As sPLA 2 subtype expression in primary human keratincytes was similar to that in HaCaT cells, we used this keratinocyte line for the analysis of sPLA 2 activity. Therefore, supernatants from HaCaT cell cultures were collected at different time points after medium change, and the enzymatic activity was determined using [ 14 C]-oleic acid-labeled E. coli membranes as substrate. sPLA 2 activity increased immediately after medium change, reaching a plateau after 4±8 h (Fig 3) , and may essentially be attributed to group X sPLA 2 , the only subtype detected in the culture supernatant (Fig 2b) . sPLA 2 activity is expressed as factor of increase in free [1-14 C]-oleic acid.
Release of free fatty acids from HaCaT cells In order to measure the release of free fatty acids HaCaT cells were prelabeled for 24 h with [1-14 C]-linoleic or [1-14 C]-oleic acid. Fresh culture medium was added and removed after different incubation times, and the amounts of free fatty acids were measured in a b-counter. The values measured in the supernatants at zero time did not exceed background values (about 40 cpm per ml).
The data in Fig 4 show an increasing release of the different fatty acids from HaCaT cells with time. The time course correlates with the increase in sPLA 2 activity in the supernatants (see Fig 3) .
Inhibition of sPLA 2 activity and fatty acid release by LY-311727 and Pyr-1 In order to con®rm that an sPLA 2 participates in the release of fatty acids, we ®rst incubated HaCaT cells in the presence of LY-311727, known as a potent inhibitor of groups IIA and V sPLA 2 (Balsinde et al, 1999) and group X sPLA 2 (Bezzine et al Total RNA was extracted from HaCaT cells, human primary keratinocytes, and human skin samples, and after DNase I treatment of the RNA probes RT-PCR was performed with speci®c primers for the human groups IIA, IID, V, and X sPLA 2 under the conditions described in Methods. The bands for group IID sPLA 2 are indicated by arrows. The upper band in the lane of group IID sPLA 2 derived from unspeci®c binding as was checked by sequence analysis. This experiment was repeated four times with similar results. RT-PCR for group IB sPLA 2 was performed in the cell cultures as well as in human skin samples, and as a positive control for human group IB sPLA 2 poly A + RNA from human lung was used. Abbreviations: HPK, human primary keratinocytes; n.t., no template. Figure 2 . Western blot analysis of group X sPLA 2 . HaCaT cells were incubated in serum-free DMEM for the periods indicated. Cell culture supernatants and cellular proteins were collected after the time points indicated. Human primary keratinocytes were cultured as described. Supernatants and cell lysates were harvested without further subcultivation of these cells. Five hundred nanograms of human recombinant groups IB, IIA, IID, V, and X sPLA 2 s were blotted and the western blot was incubated with an antiserum created against a peptide sequence speci®c for group X sPLA 2 (see Methods). Proteins from 5 ml of cell culture supernatants of HaCaT cells and human primary keratinocytes were precipitated and separated by SDS-PAGE under nonreducing conditions as described in Methods. Western blot analysis was performed using the antiserum against group X sPLA 2 at 1:150 dilution. As positive controls recombinant human groups IIA and X sPLA 2 were also blotted. One milligram protein of cell lysates from HaCaT cells or human primary keratinocytes was separated by SDS-PAGE under nonreducing conditions, and detection of group X sPLA 2 was performed as described above. Representative western blots out of three are shown for supernatants as well as for cell lysates. 2000), but not of the pancreatic-type group IB sPLA 2 or cytosolic PLA 2 (Schevitz et al, 1995) . sPLA 2 activity in the cell culture supernatants was determined after an 8 h incubation of the cells in the presence of the inhibitor. Figure 5 (a) shows that sPLA 2 activity was signi®cantly reduced by about 50%±70% with LY-311727 at a concentration of 50 mM. Fatty acid release (Fig 5b) from HaCaT cells prelabeled with [1-14 C]-oleic or [1-14 C]-linoleic acid was inhibited by about 30%±50% in the presence of LY-311727 (50 mM). These data indicate that at least a part of the released fatty acids can be attributed to group X sPLA 2 , as group IIA and group V sPLA 2 were not detected in these cells.
Accordingly, Pyr-1 [3-(2,6-dichlorophenylsulfonylamino)-4-(2-(4-acetamido) pyridyl)-5-(3-(4-¯uorophenoxy) benzyl(thio)-(1H)-pyrazole], a compound that was found to inhibit human group IIA sPLA 2 in vitro with a 120-fold selectivity compared with human group X sPLA 2 (Bezzine et al, 2000) , had no effect on the enzyme activity or on the fatty acid release measured 8 h after medium change, when given in concentrations up to 30 mM (data not shown).
Effect of phorbol ester TPA on sPLA 2 activity and fatty acid release in HaCaT cell culture supernatants Phorbol esters such as TPA are known to induce arachidonic acid release and prostaglandin synthesis in mouse keratinocytes in vitro and epidermis in vivo. This is predominantly due to the activation of cytosolic PLA 2 (Kast et al, 1993; Lo et al, 1998) . Nothing is known about the effects of phorbol esters on fatty acid metabolism and regulation of sPLA 2 s in human keratinocytes, however. We therefore asked whether TPA can modulate sPLA 2 expression and activity as well as release of fatty acids. After prelabeling with [1-14 C]-oleic or [1-14 C]-linoleic acid for 24 h and subsequent medium change, HaCaT cells were treated for 8 h with TPA (1 mM) or dimethylsulfoxide as control (0.05%), and the release of labeled fatty acids into the cell culture supernatant was analyzed. In similar experiments cell culture supernatants were collected for analysis of sPLA 2 activity.
The data in Fig 6(a) show that TPA inhibited sPLA 2 activity in the supernatant by about 50%. TPA treatment also reduced the levels of oleic as well as linoleic acid in the cell culture supernatants from prelabeled cells by about 40% (Fig 6b) .
In¯uence of TPA on mRNA expression of groups IIA, V, and X sPLA 2 We next asked whether the mRNA expression of individual sPLA 2 subtypes is affected by TPA. Recently we reported that TPA downregulates group IIA sPLA 2 mRNA induction in rat glomerular mesangial cells through a proteinkinase-C-mediated mechanism (Scholz et al, 1999) .
Performing semiquantitative RT-PCR we observed that upon medium change the mRNA level of group X sPLA 2 increased after 4 h, reaching a plateau after 8 h in untreated cells (Fig 7) . This time course corresponds to the sPLA 2 activity shown in Fig 3. In addition, mRNA levels of group V and group IIA sPLA 2 also slightly increased with time up to 24 h.
In contrast, TPA led to a marked decrease of the mRNA levels of group X sPLA 2 starting at 4±8 h and being maximally reduced at 24 h after treatment. This inhibition of mRNA expression correlated with the reduced sPLA 2 activity and fatty acid release shown in Fig 6. The mRNA levels of group IIA and group V sPLA 2 were also clearly reduced 24 h after TPA treatment compared with controls. These data suggest that the three different sPLA 2 subtypes are downregulated upon TPA application, the most prominent effect being observed for group X sPLA 2 .
A similar kinetic of group X sPLA 2 mRNA expression and downregulation by TPA was also detectable by northern blot analysis (Fig 8) . Quantitative analysis of group X sPLA 2 mRNA expression showed that mRNA levels were reduced by about 40% at 4±16 h after TPA treatment concomitantly with the decrease in sPLA 2 activity and fatty acid release (Fig 6) .
The other sPLA 2 subtypes were not detectable by this method, probably due to the low mRNA expression levels.
DISCUSSION
Several studies report on a role of sPLA 2 as a proin¯ammatory enzyme in skin of humans and animals. Overexpression of human group IIA sPLA 2 in the skin of transgenic mice resulted in hyperkeratosis, epidermal hyperplasia, and adnexal hyperplasia, which re¯ect the symptoms observed in skin disorders including human psoriasis (Grass et al, 1996) . Other groups have examined the effects of intradermal injection of sPLA 2 from snake venom and of the pancreatic-type group IB sPLA 2 in rabbit and swine (Pruzanski et al, 1986; Nair et al, 1993) causing the induction of a Figure 3 . Detection of sPLA 2 activity in HaCaT cell culture supernatants. HaCaT cells were cultured for 72 h in 10% FBS and then incubated for a further 16 h in 0.25% FBS. After medium change to serumfree DMEM cell culture supernatants were collected at once or at different time points. sPLA 2 activity was determined in the cell culture supernatants using [ 14 C]-oleic-acid-labeled E. coli membranes as described in Methods. Each value represents the mean of three independent experiments T SEM (n = 3). transient erythema as well as in¯ammatory cell in®ltration and epidermal hyperplasia. These studies show that high levels of sPLA 2 in the skin induce marked changes of skin phenotype such as epidermal hyperplasia. The acute in¯ammatory reaction upon intradermal injection may critically depend on high local sPLA 2 concentrations as Grass et al (1996) did not observe such effects in transgenic mice overexpressing group IIA sPLA 2 in the skin.
The strong effects of sPLA 2 s upon local application or ectopic expression led us to analyze the subtype spectrum of this enzyme family expressed in keratinocytes in culture and in vivo. Semiquantitative PCR and southern blot analysis indicate that HaCaT cells, human primary keratinocytes, and human skin express the four different sPLA 2 subtypes IIA, IID, V, and X. The novel human group IIE sPLA 2 (Suzuki et al, 2000) was not detectable (data not shown).
In addition, the mRNA steady-state levels in HaCaT cells coding for the different sPLA 2 s were strikingly different in the following order: group X > group V > group IIA > group IID. The mRNA levels of all sPLA 2 subtypes increased during the time course of the experiment probably due to a stimulatory effect of the medium change. Group IB sPLA 2 mRNA was not detectable in our hands in HaCaT cells, in human primary keratinocytes, or in human skin, using primers generating a positive signal with lung mRNA. Recently, group IB sPLA 2 was found by immunohistochemistry studies to be localized to the stratum corneum of human skin (Mazereeuw-Hautier et al, 2000) and was also cloned from human epidermis (Maury et al, 2000) . The authors did not examine the cross-reactivity of the antibody used with other sPLA 2 subtypes, however. The discrepancy between our results and the observations by Maury and coworkers (2000) might be explained by a weaker expression of group IB sPLA 2 in skin than in lung. Moreover, there might be a strong dilution of group IB sPLA 2 mRNA in RNA extracts from total skin biopsies, which also include some RNA from the dermis where this enzyme is not expressed (Maury et al, 2000) .
The antibody generated against the group X sPLA 2 did not cross-react with any other sPLA 2 subtypes investigated in this study and was able to detect about 200 ng per ml of group X sPLA 2 in supernatants of HaCaT as well as human primary keratinocytes. We also detected group X sPLA 2 protein in cell lysates indicating that the early increase of extracellular sPLA 2 activity was most probably due to secretion of the enzyme from intracellular stores. The action of an exogenous sPLA 2 on the outer membrane of cells is an important prerequisite for a functional role in hydrolysing phospholipids for maintaining the epidermal permeability barrier. This enzyme might contribute to the hydrolysis of polar lipids from suprabasal layers of the skin providing free fatty acids that are necessary for the synthesis of complex lipids forming the permeability barrier (Redoules et al, 1998; Ziboh et al, 2000) . This view has to be supported by immunohistochemistry determining the localization of group X sPLA 2 in human epidermis in detail. Group IIA as well as group V sPLA 2 protein would not be detected in keratinocytes in vivo and in vitro despite a modest increase of the corresponding mRNA species.
Incubation of keratinocytes with heparin or 1 M NaCl did not result in an enhanced extracellular sPLA 2 activity (data not shown) indicating the absence of membrane-associated sPLA 2 , including group IIA and group V sPLA 2 , which are known to bind tightly to cell surface proteoglycans (Cupillard et al, 1997) . Interestingly, Murakami et al (1999) showed that group X sPLA 2 does not bind to a heparin-Sepharose column, suggesting that this subtype does not associate with cell surface proteoglycans.
In summary, according to RT-PCR and northern blot and western blot analysis sPLA 2 activity in human keratinocytes is derived from group X sPLA 2 . This sPLA 2 subtype ef®ciently hydrolyzes phosphatidylcholine , a major phospholipid of the outer lea¯et of the plasma membrane. A recent report by Bezzine et al (2000) describes an ef®cient release of arachidonic acid from adherent cell cultures by exogenously added group X sPLA 2 indicating that this enzyme is involved in prostaglandin biosynthesis. This does not exclude, however, that group X sPLA 2 also hydrolyzes other phospholipid species different from phosphatidylcholine (Cupillard et al, 1997) .
The absence of group IIA or group V sPLA 2 protein despite their mRNA expression suggests that these enzymes are probably not involved in homeostatic processes in the epidermis. This is supported by the fact that group IIA sPLA 2 protein is not detectable in skin under physiologic conditions (MazereeuwHautier et al, 2000) , and the high levels of this enzyme obtained in human psoriatic skin (Andersen et al, 1994) will probably never be reached in intact nonin¯amed epidermis. In keratinocyte cultures group IIA and/or group V sPLA 2 might appear after stimulation, e.g., by proin¯ammatory cytokines or growth factors. In this respect indirect evidence was given by Thommesen et al (1998) who showed that in tumor-necrosis-factor-a-stimulated HaCaT cells the release of arachidonic acid was reduced by the sPLA 2 inhibitor LY-311727, indicating a participation of an exogenous sPLA 2 in this process. The responsible subtype was not identi®ed in HaCaT cells were treated for 8 h with the indicated concentrations of LY-311727 and then sPLA 2 activity was determined as described in Methods. Each value represents the mean of three independent experiments T SEM (n = 3). *p < 0.05, ANOVA followed by Dunnett's test. Cells were prelabeled for 24 h with [1-14 C]-oleic acid or [1-14 C]-linoleic acid (each 0.3 mCi per ml). After medium change they were incubated for 8 h in the absence or presence of LY-311727 (50 mM). Then the release of fatty acids was analyzed as described above. Each value represents the mean of three independent experiments T SEM (n = 3). #p < 0.05 (oleic acid), +p < 0.05 (linoleic acid), Student's t test. this study, however. In a recent study induction of group IIA or group V sPLA 2 protein in activated human primary keratinocytes was recently shown by Rys-Sikora et al (2000) . In their study, however, other sPLA 2 subtypes such as group X sPLA 2 were not investigated. Moreover, one has to consider that it is important whether cells were cultured in serum-containing or in serum-free medium. In our study we tried to prevent additional stimulation by serum factors, which might be the reason why we did not detect group IIA or V sPLA 2 protein.
In this study we also followed the release of oleic and linoleic acid, which are known to be preferentially localized to the sn-2 position of phospholipids. The release of free fatty acids from cells represents a steady-state equilibrium between hydrolysis and the reesteri®cation of the free fatty acids. Thus, the increased release of oleic acid over linoleic acid (Fig 4) may be due to a less effective reincorporation of this fatty acid into phospholipids.
Using the sPLA 2 inhibitor LY-311727, we found a partial inhibition of sPLA 2 activity and fatty acid release from HaCaT cells. This substance is known to inhibit a variety of sPLA 2 s (Chen and Dennis, 1998; Bezzine et al, 2000) , whereas it does not inhibit intracellular PLA 2 s or group IB sPLA 2 (Schevitz et al, 1995) . In cultures of rat mesangial cells that release group IIA sPLA 2 (Pfeilschifter et al, 1993) , 10 mM of this compound completely inhibited the enzyme activity (unpublished results). In HaCaT cells, however, a concentration of 50 mM was required to inhibit sPLA 2 activity in the supernatant by 70%. Murakami et al (1999) reported that group X sPLA 2 activity was indeed resistant to 10 mM of LY-311727, and Bezzine et al (2000) showed a 2.5-fold selectivity of LY-311727 in vitro in inhibiting human group IIA versus group X, which is only modest and probably not enough to distinguish between these two enzymes in cell studies. Therefore, LY-311727 can only be considered as a general inhibitor of sPLA 2 activity with a broad speci®city for the different sPLA 2 subtypes. Pyr-1, another sPLA 2 inhibitor that has a 120-fold selectivity for human group IIA compared with human group X sPLA 2 in vitro (Bezzine et al, 2000) , had no inhibitory effect on the sPLA 2 activity and fatty acid release in HaCaT cells (data not shown), strongly suggesting that group IIA sPLA 2 activity does not contribute to these processes. Up to now, no speci®c inhibitor of the group X sPLA 2 is available. It would be very interesting to study the effects of such a speci®c inhibitor on epidermis in vivo, as suppression of sPLA 2 activity in general has been shown to disrupt the permeability barrier and to disturb epidermal homeostasis (Mao-Qiang et al, 1995) . According to the selective expression and the characteristics of enzymatic activity (see above) group X sPLA 2 appears to be the PLA 2 subtype involved in the maintenance of epidermal integrity and function.
We cannot exclude that cytosolic PLA 2 s also contribute to fatty acid release from HaCaT cells. Treatment of the cells with methyl arachidonyl¯uorophosphonate, a potent inhibitor of this enzyme and, with a lower potency, of a Ca 2+ -independent cytosolic PLA 2 (group VI PLA 2 ; Balsinde et al, 1999) , inhibited the release of linoleic acid by 20%±30%, but not that of oleic acid, from HaCaT cells. Selectivity for the hydrolysis of polyunsaturated fatty acids is known to be a characteristic property of group IV cytosolic PLA 2 . The fact that all fatty acids were at least partially reduced by LY-311727, however, supports the involvement of an sPLA 2 in this process. . Supernatants were collected and sPLA 2 activity was measured as described in Methods. Each value represents the mean of three independent experiments T SEM (n = 3). *p < 0.05, Student's t test. Cells were prelabeled with different [1-14 C]-labeled fatty acids (each 0.3 mCi per ml) as indicated. After medium change cells were further incubated for 8 h in the absence or presence of TPA (1 mM). Analysis of fatty acids released into the cell culture supernatants was performed as described in Methods. Each value represents the mean of three independent experiments T SEM (n = 3). #p < 0.05 (oleic acid), +p < 0.05 (linoleic acid), Student's t test. A disruption of the epidermal layers occurs during in¯ammatory processes in the skin. In this respect the phorbol ester TPA, which is used as a tumor promoter in the mouse multistage skin carcinogenesis model (for review, see Marks and Fu Èrstenberger, 1990) , is per se a potent in¯ammatory substance leading to hyperplasia and hyperkeratosis. Moreover, TPA is a strong activator of cytosolic PLA 2 in mouse keratinocytes resulting in increased release of arachidonic acid and subsequent eicosanoid formation (Kast et al, 1993; Lo et al, 1998 ) through induction of cyclooxygenase 2 (Scholz et al, 1995; Mu Èller-Decker et al, 1998) and lipoxygenase gene expression (Krieg et al, 1998) . Incubation of HaCaT cells as a human keratinocyte model with TPA reduced sPLA 2 activity by about 50% and fatty acid release by about 40%. We reported here that all the sPLA 2 subtypes IIA, V, and X were downregulated by TPA at the transcriptional level in HaCaT cells. A clear decrease of sPLA 2 enzyme activity and fatty acid release was observed in parallel. TPA was also found to inhibit the cytokineinduced mRNA expression and activity of group IIA sPLA 2 in rat mesangial cells (Scholz et al, 1999) . Whether or not TPA elicits similar effects in skin in vivo remains to be elucidated. A hallmark of TPA action both in mouse and in human skin is the induction of in¯ammatory processes (Marks and Fu Èrstenberger, 1990) . In fact, certain sPLA 2 subtypes, which are expressed at very low levels in healthy skin, are upregulated under in¯ammatory conditions on mRNA and protein level and might contribute to proin¯ammatory eicosanoid formation such as group IIA sPLA 2 in activated keratinocytes (Rys-Sikora et al, 2000) and psoriatic tissue (Andersen et al, 1994) , or group V in mouse macrophages or mast cells (Balboa et al, 1996; Reddy et al, 1997; Bingham et al, 1999) .
A role of group X sPLA 2 in the TPA-stimulated early release of arachidonic acid from HaCaT cells might be hypothesized, as it was shown that human group X sPLA 2 releases arachidonic acid for cyclooxygenase-2-dependent prostaglandin E 2 formation when added exogenously to adherent mammalian cells (Bezzine et al, 2000) . From the time course of downregulation of group X sPLA 2 starting between 4 and 8 h, however, and that of phorbol-esterinduced prostaglandin formation starting after 6±8 h, we suggest that group X sPLA 2 -catalyzed arachidonic acid release is not a prerequisite for the initiation of prostaglandin synthesis induced by TPA. This was supported by the observation that treatment of the cells with TPA in the presence of 50 mM of LY-311727, which signi®cantly reduced fatty acid release, did not result in reduced prostaglandin E 2 formation (unpublished observation).
The mechanism by which TPA downregulates the different sPLA 2 subtypes in HaCaT cells is unknown. TPA was shown to activate different transcription factors such as AP-1 and ets via protein kinase C (Dong et al, 1997; Sark et al, 1998) , which may result in inhibition of sPLA 2 gene expression. Another possibility is the modulation of the cytokine-induced signaling pathway upstream of the transcription. In this respect we found that TPAactivated protein kinase C inhibits IL-1b-stimulated activation of a neutral sphingomyelinase during the ®rst 10 min after treatment of mesangial cells (Kaszkin et al, 1998) , indicating that TPA interferes with an IL-1-receptor-associated signaling molecule such as the IL-1-receptor-associated kinase or other IL-1b-activated downstream kinases (for review, see Auron, 1998) .
On the other hand this raised the question: what triggers the permanent release of group X sPLA 2 into the supernatant of proliferating keratinocytes? These cells are known to spontaneously release growth factors such as vascular endothelial growth factor (VEGF) (Weninger et al, 1998; Charvat et al, 1999) and cytokines such as IL-6 (Aragane et al, 1996) . It might be speculated that such cytokines maintain a constant secretion of group X sPLA 2 in an autocrine manner. In skin repair processes these cytokines have important functions in stimulating mechanisms crucial for wound healing such as induction of VEGF expression or formation of nitric oxide (Frank et al, 1995 (Frank et al, , 1998 . These factors are necessary for angiogenesis, wound closing, and epidermal reorganization. It seems reasonable to propose also a physiologic role of group X sPLA 2 in keratinocytes in these processes, which has to be investigated in future studies. TPA might interfere with group X sPLA 2 secretion by inhibiting the cytokine-mediated signal transduction. Future studies will further elucidate the mechanisms of the negative modulation of sPLA 2 induced by TPA.
